Navigation Links
ProteoTech Receives Funding From The Michael J. Fox Foundation for Parkinson's Disease Research to Develop Tools for Imaging Alpha-Synuclein Aggregation in Living Parkinson's Brain
Date:3/2/2009

KIRKLAND, Wash., Feb 26 /PRNewswire/ -- ProteoTech Inc. announced today that it has been awarded a grant from The Michael J. Fox Foundation for Parkinson's Disease Research. In collaboration with Avid Radiopharmaceuticals Inc. (Philadelphia, PA), ProteoTech scientists will utilize ProteoTech's small molecule platform drug technology to develop new imaging agents that will allow doctors to use PET imaging to identify and determine the extent of alpha-synuclein accumulation in the living human brain. Alpha-synuclein is a major protein identified in Lewy bodies in the Parkinson's disease brain, and its accumulation in brain is believed to be important in the motor dysfunction observed in Parkinson's patients. The one-and-a-half year project entitled "18-F-labeled Alpha-Synuclein Ligands for PET Imaging of Lewy Bodies" will be led by Dr. Alan Snow, Chairman, President & Chief Scientific Officer of ProteoTech, and Dr. Franz Hefti, Chief Scientific Officer of Avid Radiopharmaceuticals Inc.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090226/SF76109LOGO)

ProteoTech is currently in its 4th year of a LEAPS award funded by The Michael J. Fox Foundation for Parkinson's Disease Research to develop a new small molecule targeting alpha-synuclein in Parkinson's brain. ProteoTech's Synuclere(TM) has been demonstrated to inhibit alpha-synuclein aggregation in the brains of genetically engineered mice that develop motor dysfunction, when alpha-synuclein deposits aggregate and accumulate in brain. The LEAPS award consortium led by Dr. Alan Snow of ProteoTech includes research teams from University of California-San Diego, Boston University, Boston College and Medchem Source Inc.

About ProteoTech: ProteoTech is a private drug development Company founded in 1996 that is a world-leader in therapeutics targeting amyloid diseases. With over 175 patents in its intellectual property estate, ProteoTech is in human clinical trials for its orally active small molecule drug Exebryl-1 for the treatment of mild-to-moderate Alzheimer's disease. The Company is in late-stage pre-clinical development with Synuclere(TM) for the treatment of Parkinson's disease, and Systebryl(TM) for the treatment of Systemic Amyloidosis. ProteoTech is also in late stage pre-clinical development for a novel small peptide called PeptiClere(TM) as a nasal spray for the treatment of Alzheimer's disease. Lastly, ProteoTech is developing a novel small molecule compound for the treatment of amyloidosis associated with type 2 diabetes. For further information, please visit the Company's website at www.proteotech.com or contact us at info@proteotech.com


'/>"/>
SOURCE ProteoTech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ProteoTech to Present at Rodman & Renshaws 10th Annual Healthcare Conference
2. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
3. DaVita Receives Civil Complaint
4. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
5. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
6. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
7. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
8. UT Southwesterns obesity research receives $22 million NIH Roadmap grant
9. Temple Emergency Medicine receives $1.8M to find best MRSA treatment
10. Prime Therapeutics Receives TIPPS Certification
11. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
(Date:6/24/2016)... ... ... People across the U.S. are sharpening their pencils and honing their writing ... which patients and their families pay tribute to a genetic counselor by nominating him ... Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, Genome ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions ... initiated cultivation and processing operations at its production facility, and opened its first ... is the manufacturer of a complete system of proactive air and surface purification ...
(Date:6/24/2016)... ... ... Venture Construction Group (VCG) sponsors Luke’s Wings 5th Annual ... Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The event raised funds ... been wounded in battle and their families. Venture Construction Group is a 2016 Silver ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)...  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported ... required to build a strong and stable market for ... on the OTC Markets-pink current trading platform. ... are seeing an anomaly in market trading activities that ... the Company, but shareholders and market players as well. ...
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... ALEXANDRIA, Va. , June 24, 2016 ... a set of recommendations that would allow ... information (HCEI) with entities that make formulary and coverage ... determine the "value" of new medicines. The ... that does not appear on the drug label, a ...
Breaking Medicine Technology: